Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Viventia Biotech was incorporated in 1983 under the name Illecillewaet Exploration Ltd. Since this time, the company has undergone various reorganisations and mergers, during which it was also known as Wirlwind Resources Ltd, Spirit Resources Ltd, Hygeia Holdings/Hygeia Wyoming and Novopharm Biotech Inc.